Skip to main content
Displaying 128 of 2876 articles.

Researchers capture never-before-seen view of gene transcription

New tech reveals findings that address long-standing theories about how bacteria begin the process of making RNA from DNA.

Elizabeth Campbell launches Laboratory of Molecular Pathogenesis

The infectious disease specialist will continue her groundbreaking work on the transcriptomes of the pathogens behind tuberculosis and Covid.

How one scientist's fascination with RNA changed medicine forever

Thomas Tuschl has devoted his career to making discoveries that bridge the gap between bench and business—and have resulted in entirely new classes of drugs.

New Mtb study offers a novel paradigm for understanding bacterial transcription

A novel sequencing technique reveals a genetic trick TB may be using to evade the immune system and resist antibiotics.

A new way of thinking about how organ architecture develops 

By focusing on the emergent features of cell collectives, instead of individual cells, scientists forge a new path for understanding how organs develop their architecture.   

How intricate patterns arise in developing tissues

In developing bird skin, immature cells move around and form intricate patterns. Scientists are zeroing in on the mechanical forces guiding the process.

One protein's surprising partnership with single-stranded DNA

Linker histone H1 appears capable of distinguishing between single-stranded and double-stranded DNA, suggesting that its role in maintaining our genomes extends far beyond that of keeping chromosomes compact.

A synthetic antibiotic may help turn the tide against drug-resistant bacteria

The compound attacks MRSA, C. diff, and several other deadly pathogens. Its discovery demonstrates the power of combining computational biology, genetic sequencing, and synthetic chemistry to study bacterial evolution.

Titia de Lange elected to the Royal Society

She receives the honor for elucidating mechanisms of telomere protection and genome maintenance.

How a narrow-spectrum antibiotic takes aim at C. diff

A new study reveals how the drug fidaxomicin selectively targets a dangerous pathogen without causing harm to beneficial bacteria. The findings could inform the development of new narrow-spectrum antibiotics for treating other types of infection.
View
View